These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18070860)

  • 1. A case report with ziprasidone-induced catatonic symptoms.
    Markham-Abedi C; McNeely C; de Leon J
    J Neuropsychiatry Clin Neurosci; 2007; 19(4):476-7. PubMed ID: 18070860
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of catatonia in a 14-year-old girl with schizophrenia treated with electroconvulsive therapy.
    Häßler F; Reis O; Weirich S; Höppner J; Pohl B; Buchmann J
    Z Kinder Jugendpsychiatr Psychother; 2013 Jan; 41(1):69-74. PubMed ID: 23258439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone.
    Scahill L; Blair J; Leckman JF; Martin A
    J Psychopharmacol; 2005 Mar; 19(2):205-6. PubMed ID: 15728441
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tardive dyskinesia in 2 patients treated with ziprasidone.
    Ananth J; Burgoyne KS; Niz D; Smith M
    J Psychiatry Neurosci; 2004 Nov; 29(6):467-9. PubMed ID: 15644988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient agranulocytosis associated with ziprasidone in a 45-year-old man on hemodialysis.
    Iskandar JW; Vance JE; Kablinger A; Kavuru B
    J Clin Psychopharmacol; 2015 Jun; 35(3):347-8. PubMed ID: 25874914
    [No Abstract]   [Full Text] [Related]  

  • 7. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
    Ku HL; Su TP; Chou YH
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):963-4. PubMed ID: 16624468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible ziprasidone-induced mania.
    Larson MF; Hauser A
    J Am Acad Child Adolesc Psychiatry; 2003 Sep; 42(9):1012; discussion 1012-3. PubMed ID: 12964565
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
    Mencacci C;
    Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged erections associated with ziprasidone treatment: a case report.
    Reeves RR; Kimble R
    J Clin Psychiatry; 2003 Jan; 64(1):97-8. PubMed ID: 12590634
    [No Abstract]   [Full Text] [Related]  

  • 11. Ziprasidone approved.
    Hirsch M
    Harv Ment Health Lett; 2001 Jun; 17(12):8. PubMed ID: 11439926
    [No Abstract]   [Full Text] [Related]  

  • 12. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comments on the report of neuroleptic malignant syndrome induced by ziprasidone.
    Margetic B; Aukst-Margetic B
    World J Biol Psychiatry; 2007; 8(2):131-2; author reply 133-4. PubMed ID: 17455107
    [No Abstract]   [Full Text] [Related]  

  • 14. Repeated acute dystonia following administration of amisulpride and ziprasidone in a patient with iron deficiency.
    Chen HK; Chen CK; Tzeng NS
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1615-6. PubMed ID: 18597910
    [No Abstract]   [Full Text] [Related]  

  • 15. Mania associated with initiation of ziprasidone.
    Nolan BP; Schulte JJ
    J Clin Psychiatry; 2003 Mar; 64(3):336. PubMed ID: 12716277
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyperosmolar hyperglycemic state associated with ziprasidone treatment: a case report.
    Létourneau G; Abdel-Baki A; Dubreucq S; Mahone M; Granger B
    J Clin Psychopharmacol; 2011 Oct; 31(5):671-3. PubMed ID: 21881458
    [No Abstract]   [Full Text] [Related]  

  • 17. D2-blockade and possible ziprasidone-induced galactorrhea.
    Ramadan M; Khan A; Preskorn S
    Int Clin Psychopharmacol; 2005 Mar; 20(2):113-4. PubMed ID: 15729088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR; Pandolfo G; Micò U; Lamberti Castronuovo E; Abenavoli E; Scimeca G; Spina E; Zoccali R; Bruno A
    J Clin Psychopharmacol; 2014 Feb; 34(1):129-33. PubMed ID: 24145221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
    Kane JM
    J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
    [No Abstract]   [Full Text] [Related]  

  • 20. Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial.
    Mautone A; Scarone S;
    Pharmacopsychiatry; 2011 Jul; 44(5):173-8. PubMed ID: 21751127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.